# BLeeding Events and Maintenance DoSe of PraSugrel

Study · id `cardio:ct-nct01790854` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01790854](<https://clinicaltrials.gov/study/NCT01790854>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT01790854

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 195 participants.

## Technical summary

Registry record NCT01790854. Randomized; no masking; primary purpose treatment. Start 2012-11 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 195 participants (enrolled count; ClinicalTrials.gov record NCT01790854, source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)
- Start date: 2012-11 (registry gives no type) (ClinicalTrials.gov record NCT01790854, source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01790854, source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)
- Completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01790854, source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)
- Countries: Italy (ClinicalTrials.gov record NCT01790854, source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "TERMINATED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01790854-2016-07-29`, retrieved 2026-10-31)

## The registry's words

- Brief title: BLeeding Events and Maintenance DoSe of PraSugrel
- Acronym: BLESS
- Condition: Adverse Reaction to Antiplatelet Agent
- Condition: Acute Coronary Syndrome
- Intervention (Drug): Prasugrel dose 5 mg/day
- Intervention (Drug): Prasugrel dose 10 mg/day
- Lead sponsor: David Antoniucci
- Lead sponsor class: OTHER
- Collaborator: A.R. CARD Onlus Foundation
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Prasugrel (`cardio:prasugrel`)
- Registry intervention is a member of this class by a sourced record link: P2Y12 inhibitors (drug class) (`cardio:p2y12-inhibitors`)

## Provenance

Content hash: 372fafb219697d3b53898c79635eca136d05454fd6892c3683ea4309e611f6c4
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
